IP finance

"Where money issues meet IP rights". This weblog looks at financial issues for intellectual property rights: securitisation and collateral, IP valuation for acquisition and balance sheet purposes, tax and R&D breaks, film and product finance, calculating quantum of damages--anything that happens where IP meets money.

Monday, 30 March 2020

Novartis, the Good Samaritan

›
As discussed in a previous post , the Covid-19 pandemic is an excellent opportunity for the pharmaceutical industry to demonstrate its commi...
1 comment:
Saturday, 28 March 2020

US FTC and DOJ, Antitrust Division Modify Antitrust Procedures in Light of Coronavirus

›
The Federal Trade Commission and the U.S. Department of Justice, Antitrust Division have modified procedures for antitrust review and pr...
Saturday, 21 March 2020

Is it Time to Increase Funding to Universities for Research and Development in the United States?

›
In a document released by the Association of American Universities (AAU), Mary Sue Coleman, president of the organization, discusses Vannev...
Friday, 20 March 2020

Will the US Government, California and Health Insurers Produce Treatments for Covid-19 for the World?

›
Neil Wilkof wrote on the IPKat blog today that the Israeli government has essentially issued permits under Israeli law to import generic ve...
Thursday, 19 March 2020

U.S. Department of Energy Grants for Scientific Discovery through Advanced Computing Teams

›
The U.S. Department of Energy is offering $60 million in grants available to universities, private industry and others to utilize nationa...
Tuesday, 17 March 2020

The Coronavirus Pandemic -- An Opportunity for the BioPharmaceutical Industry?

›
The Santa Cruz Sentinel (Wow!) has an excellent news article about a Gilead Sciences drug used (in combination with other treatments) to...
Monday, 16 March 2020

Legislation Introduced to Raise Manufacturing of Active Pharmaceutical Ingredients in the United States

›
On March 11, 2020, Senators Blackburn and Menendez introduced a bill, Securing America’s Medicine Cabinet, designed to raise the manufact...

Proposed Act on Curbing Anticompetitive Conduct in the United States

›
On March 10, 2020, former Presidential Candidate and Senator Amy Klobuchar introduced legislation designed to address abuses of market po...
Friday, 6 March 2020

Alliance for Regenerative Medicine: 2019 is Second Best Year in History for Regenerative Medicine Financing

›
The Alliance for Regenerative Medicine (ARM) has recently released its annual report .  Notably, ARM states that 2019 was the second-best...
‹
›
Home
View web version
Powered by Blogger.